S&P Futures
3,808.75-8.00(-0.21%)Dow Futures
31,207.00-29.00(-0.09%)Nasdaq Futures
12,654.50-27.25(-0.21%)
CASI Pharmaceuticals, Inc. (CASI)
Chart Events
Performance Outlook
| Previous Close | 2.4700 |
| Open | 2.4500 |
| Bid | 0.0000 x 1300 |
| Ask | 0.0000 x 1800 |
| Day's Range | 2.3700 - 2.5200 |
| 52 Week Range | 1.1500 - 3.9000 |
| Volume | 208,663 |
| Avg. Volume | 492,498 |
| Market Cap | 296.226M |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- PR Newswire
CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced preliminary and unaudited revenues for the fourth quarter and full-year 2020 and provided an update on key highlights for 2021.
- PR Newswire
CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that its partner BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced positive interim results from the Phase I/IIa trial of the novel anti-FcγRIIB antibody BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) in patients with indolent relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
- PR Newswire
CASI Pharmaceuticals Partner, BioInvent, To Host Key Opinion Leader Call On BI-1206 For Relapsed Or Refractory Non-Hodgkin's Lymphoma
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that its partner BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy today announces that it will host a Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin's Lymphoma on Thursday, January 28, 2021 at 11:30 a.m. Eastern Time (5:30 p.m. CET).
